An ageing and overweight population only serves to exacerbate the situation. By 2050, 16% of the world’s population will be over 65. Overweight people are 4 to 5 times more likely to suffer from arthritis. It’s also the fit and healthy who can suffer. In a panel of 284 professional athletes interviewed, almost 50% were found to have osteoarthritis.
Tell-tale signs of osteoarthritis are joint (hand, knee, hip) stiffness in the morning, joint pain (whether active or inactive), swelling, tender and warm joints, and limited range of movement.
Aptissen revolutionized the market by launching the first HA product of the 2nd generation: SynolisTM VA which combines Hyaluronic Acid and Sorbitol, an antioxidant. SynolisTM VA’s viscoelastic properties (a patented formulation) are similar to those found in young, healthy synovial fluid. This results in rapid mobility recovery and fast, long-lasting pain relief associated with excellent safety. As such, SynolisTM VA is a premium innovative product which meets both patients and doctors expectations.
Our very raison d’être is pain relief for our patients. We pride ourselves in deliver life-changing orthobiologic solutions. As a proudly Swiss company, we’re committed to proven products and guiding our partners with wise counsel.
In this day and age, a modern website is the signature of an innovative medical device company.
Advancing Intra Articular Therapy For Osteoarthritis: Experience, Innovations and Improving Patient Outcomes
In order to continue the exponential growth, Aptissen has expanded its management team.